VALTOCO features 5-dose packaging to better support patient care. For more information, click here.
Just when you think your patients are well controlled, seizure episodes can come out of nowhere.
Prepare them to stop seizures in their tracks.
VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.1
Just when you think your patients are well controlled, seizure episodes can come out of nowhere.
Prepare them to stop seizures in their tracks.
VALTOCO is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.1
Prepare your patients with rapid, reliable, ready seizure treatment
In open-label safety studies:
The median time to seizure cessation when VALTOCO was administered within 5 minutes of seizure onset was 2 minutes2,*,†
87% of seizure episodes used a single dose over a 24-hour period3,*
A majority of patients aged ≥6 years returned to their usual selves within 1 hour of VALTOCO administration4,‡
The number of days between treated episodes of frequent seizures doubled over a 12-month period in patients using VALTOCO5,§
The median time to seizure cessation when VALTOCO was administered within 5 minutes of seizure onset was 2 minutes2,*,†
87% of seizure episodes used a single dose over a 24-hour period3,*
A majority of patients aged ≥6 years returned to their usual selves within 1 hour of VALTOCO administration4,‡
The number of days between treated episodes of frequent seizures doubled over a 12-month period in patients using VALTOCO5,§
*Post hoc analyses from Study 05, a 12-month, open-label, repeat-dose safety study in patients 6 to 65 years of age, and Study 08, an open-label, pharmacokinetic and repeat-dose safety study in patients 2 to 5 years of age; the studies did not have prespecified efficacy endpoints.6,7
†The median time to seizure cessation for all seizures treated with VALTOCO regardless of time to administration was 3 minutes (n=3444; range, 0-1440 minutes).2
‡59% of patients returned to their usual selves within 60 minutes of administration of VALTOCO as recorded in patient and caregiver surveys in Study 05.4
§Intervals between treated episodes of frequent seizures were measured in days between VALTOCO doses using seizure diary data from the open-label safety Study 05 in patients aged 6 to 65 years. The analysis included 76 of 163 patients (47%) who received 1 dose of VALTOCO and had 1 measurable interval in 4 consecutive 90-day periods. Second doses given within 24 hours of the initial dose were excluded from the analysis.5
